JP2017525738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525738A5 JP2017525738A5 JP2017512286A JP2017512286A JP2017525738A5 JP 2017525738 A5 JP2017525738 A5 JP 2017525738A5 JP 2017512286 A JP2017512286 A JP 2017512286A JP 2017512286 A JP2017512286 A JP 2017512286A JP 2017525738 A5 JP2017525738 A5 JP 2017525738A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pterostilbene
- skin
- composition according
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 20
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 16
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 9
- 208000009621 actinic keratosis Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 6
- 230000004224 protection Effects 0.000 claims description 6
- -1 pterostilbene compound Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 230000005778 DNA damage Effects 0.000 claims description 4
- 231100000277 DNA damage Toxicity 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 230000004888 barrier function Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000011379 keloid formation Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000036572 transepidermal water loss Effects 0.000 claims description 4
- 208000003373 basosquamous carcinoma Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000001767 chemoprotection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046068P | 2014-09-04 | 2014-09-04 | |
| US62/046,068 | 2014-09-04 | ||
| PCT/US2015/048422 WO2016036999A1 (en) | 2014-09-04 | 2015-09-03 | Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017525738A JP2017525738A (ja) | 2017-09-07 |
| JP2017525738A5 true JP2017525738A5 (enExample) | 2018-10-04 |
Family
ID=55436471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512286A Pending JP2017525738A (ja) | 2014-09-04 | 2015-09-03 | 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9980924B2 (enExample) |
| EP (1) | EP3194032B1 (enExample) |
| JP (1) | JP2017525738A (enExample) |
| KR (1) | KR20170045343A (enExample) |
| CN (1) | CN107106877A (enExample) |
| AU (1) | AU2015311799A1 (enExample) |
| BR (1) | BR112017004304B1 (enExample) |
| CA (1) | CA2959756C (enExample) |
| MX (1) | MX375612B (enExample) |
| WO (1) | WO2016036999A1 (enExample) |
| ZA (1) | ZA201701510B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375612B (es) | 2014-09-04 | 2025-03-06 | Univ California | Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel. |
| EP3501490B1 (en) * | 2016-08-17 | 2023-08-30 | Tomoike Bio Ltd. | Composition for external use that includes pterostilbene glycoside |
| JP7061766B2 (ja) * | 2017-09-20 | 2022-05-02 | 学校法人同志社 | Ｄｊ－１タンパク質産生促進用組成物 |
| CA3163065A1 (en) | 2019-12-30 | 2021-07-08 | George P. Majewski | Ppar agonist complex and methods of use |
| EP4029496A1 (en) * | 2021-01-18 | 2022-07-20 | Universitat de València | Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2820975B1 (fr) | 2001-02-21 | 2004-03-12 | Oreal | Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene |
| US20090047309A1 (en) | 2007-08-13 | 2009-02-19 | Maes Daniel H | Cosmetic methods and compositions for repairing human skin |
| US8703161B2 (en) | 2007-08-13 | 2014-04-22 | Elc Management, Llc | Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators |
| US20100240767A1 (en) * | 2009-03-23 | 2010-09-23 | Muhammed Majeed | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof |
| EP2322159A1 (en) * | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| US8841350B2 (en) * | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| JP2013075851A (ja) * | 2011-09-30 | 2013-04-25 | Fujifilm Corp | 皮膚外用剤 |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| CN103239540B (zh) * | 2013-04-03 | 2014-11-12 | 广东药学院 | 一种凉血愈伤方提取物及治疗皮肤烧伤的复方白藜芦醇凉血愈伤油制剂 |
| WO2016037007A1 (en) | 2014-09-04 | 2016-03-10 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia |
| MX375612B (es) | 2014-09-04 | 2025-03-06 | Univ California | Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel. |
-
2015
- 2015-09-03 MX MX2017002818A patent/MX375612B/es active IP Right Grant
- 2015-09-03 KR KR1020177009080A patent/KR20170045343A/ko not_active Ceased
- 2015-09-03 AU AU2015311799A patent/AU2015311799A1/en not_active Abandoned
- 2015-09-03 US US14/845,173 patent/US9980924B2/en active Active
- 2015-09-03 JP JP2017512286A patent/JP2017525738A/ja active Pending
- 2015-09-03 CA CA2959756A patent/CA2959756C/en active Active
- 2015-09-03 CN CN201580059094.2A patent/CN107106877A/zh active Pending
- 2015-09-03 BR BR112017004304-1A patent/BR112017004304B1/pt not_active IP Right Cessation
- 2015-09-03 EP EP15838274.7A patent/EP3194032B1/en active Active
- 2015-09-03 WO PCT/US2015/048422 patent/WO2016036999A1/en not_active Ceased
-
2017
- 2017-02-28 ZA ZA2017/01510A patent/ZA201701510B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525738A5 (enExample) | ||
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| JP2016538271A5 (enExample) | ||
| IL316851A (en) | Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2016532722A5 (enExample) | ||
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| WO2013019058A3 (en) | Pharmaceutical composition for inhibiting cancer recurrence or metastasis | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
| PH12013500923A1 (en) | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative | |
| WO2013166177A3 (en) | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| WO2010039654A3 (en) | Topical treatment of skin infection | |
| NZ594184A (en) | Skin treatment | |
| EP4431155A3 (en) | Pharmaceutical composition, preparation and uses thereof | |
| WO2014043230A3 (en) | Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof | |
| MY160377A (en) | Topical pharmaceutical compositions | |
| WO2014052780A3 (en) | Compositions and methods of use of an inappetance-controlling compound | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| JP2014530204A5 (enExample) |